September 24, 2020

Double-Blind, Randomized, Placebo-Controlled Trial with N-Acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• In a randomized, placebo-controlled trial of N-acetylcysteine (NAC) in Brazil among people with severe COVID-19, the frequency of intubation was similar in the NAC (20.6%) vs. placebo (23.9%) groups (p=0.68). No differences in secondary endpoints (ICU admission, time in ICU, and mortality) were observed.

de Alencar et al. (Sept 23, 2020). Double-Blind, Randomized, Placebo-Controlled Trial with N-Acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1443